Ex vivo studies sit between test-tube experiments and full clinical trials on the evidence scale
Several intervention strategies were designed to affect HGF/c-Met signaling: inhibitors of HGF activation, HGF neutralizing antibodies Rilotumumab (AMG102), Ficlatuzumab (AV-299) and TAK701 [61], c-Met antagonists Onartuzumab, CE-355621, selective inhibitors of c-Met kinase activity Tivantinib, AMG-337, AMG-458, Foretinib, PHA-665725, MK-2461, PF-04217903 and SU11274, and nonselective multitarget inhibitors of RTK including c-Met such as Crizotinib and Cabozantinib
TB-500 and thymosin beta-4 for bone repair Thymosin beta-4 (abbreviated as Tb4) is a naturally occurring 43-amino acid peptide that plays fundamental roles in cellular migration, tissue regeneration, and wound healing throughout the body
Wednesdays approval is backed by data from two Phase III studiesBE HEARD I and BE HEARD II
We strive to treat everyone the way we would want to be treated
J Autism Dev Disord 2012